Stockscreener 앱 받기
25.24
2.73%
0.67
시간 외 거래:
25.19
-0.05
-0.20%
Agios Pharmaceuticals Inc 주식(AGIO)의 최신 뉴스
What drives Agios Pharmaceuticals Inc stock priceStock Buyback Updates & Access Powerful Market Insights - earlytimes.in
9 Oversold Biotech Stocks to Invest In - Insider Monkey
The week in pharma: action, reaction and insight – week to November 21 - The Pharma Letter
Agios rebounds as Leerink upgrades to Outperform on selloff - MSN
Why Agios Plummeted, Losing Half Its Value, While Fulcrum Surged - MSN
AGIO: JP Morgan Lowers Price Target to $20.00 -- Maintains Neutral Rating | AGIO Stock News - GuruFocus
Agios Pharma stock price target lowered to $48 at H.C. Wainwright on mixed trial data - Investing.com Canada
Leerink Partners upgrades Agios Pharma stock on thalassemia potential By Investing.com - Investing.com Canada
AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results - Yahoo Finance
How Recent Events Are Reshaping the Agios Pharmaceuticals Investment Story - Yahoo Finance
Agios slumps on mixed Phase III trial of mitapivat in sickle cell disease - The Pharma Letter
Agios stock rebounds as Leerink upgrades (AGIO:NASDAQ) - Seeking Alpha
Will Agios Pharmaceuticals Inc. (8AP) stock beat growth indexesStock Surge & Safe Capital Allocation Plans - newser.com
Agios Pharmaceuticals Stock Suffers Record Wipeout As Wall Street Warns Of 'Uncertain' Regulatory Path For Sickle Cell Drug - Stocktwits
Agios Pharma stock plunges on mixed Pyrukynd sickle cell trial results - Investing.com India
AGIO: Leerink Partners Upgrades Rating, Lowers Price Target | AG - GuruFocus
AGIO: Goldman Sachs Lowers Price Target, Maintains Neutral Ratin - GuruFocus
Leerink Partners upgrades Agios Pharma stock on thalassemia potential - Investing.com India
Agios Pharmaceuticals price target lowered to $25 from $40 at Goldman Sachs - TipRanks
Agios Pharmaceuticals (AGIO) Receives Upgrade Despite Mixed Tria - GuruFocus
Nvidia To Rally Around 72%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
RBC Downgrades Agios Pharmaceuticals to Sector Perform From Outperform, Cuts Price Target to $28 From $57 - MarketScreener
Leerink Partners Upgrades Agios Pharmaceuticals to Outperform From Market Perform, PT is $34 - MarketScreener
AGIO: HC Wainwright Lowers Price Target But Maintains Buy Rating - GuruFocus
Published on: 2025-11-20 04:28:25 - newser.com
Published on: 2025-11-20 00:18:11 - newser.com
How Agios Pharmaceuticals Inc. (8AP) stock moves on employment dataJuly 2025 Market Mood & Precise Entry and Exit Recommendations - newser.com
Published on: 2025-11-19 21:36:35 - newser.com
Will Agios Pharmaceuticals Inc. (8AP) stock hit analyst forecasts - newser.com
How Agios Pharmaceuticals Inc. (8AP) stock correlates with oil marketsOil Prices & Fast Entry and Exit Trade Plans - newser.com
Published on: 2025-11-19 18:19:52 - newser.com
Agios Pharma stock price target cut to $32 from $54 at BofA on SCD trial results By Investing.com - Investing.com South Africa
Agios Makes Case For Pyrukynd Approval In SCD Despite Mixed Phase III Results - Citeline News & Insights
Will Agios Pharmaceuticals Inc. stock see PE expansionProduct Launch & High Return Trade Opportunity Guides - newser.com
Agios Pharmaceuticals Plunges Over 50% as Sickle Cell Drug Delivers Mixed Phase 3 Results - Markets Financial Content
Agios planning sNDA on mixed sickle cell data for mitapivat - BioWorld MedTech
This Biotech Just Lost Half Its Value As Its Rival Celebrated - Investor's Business Daily
Agios reports mixed results in sickle cell disease trial of mitapivat - Investing.com Nigeria
Agios Pharma: Study Fail May Affect Mitapivat TDT ApprovalExpect More Volatility (AGIO) - Seeking Alpha
Agios Pharma stock price target cut to $32 from $54 at BofA on SCD trial results - Investing.com UK
Agios Shares Plunge 50% After Mixed Phase 3 RISE UP Results For Mitapivat - Nasdaq
Why Shares in Agios Pharmaceuticals Got Crushed Today - AOL.com
Agios Pharmaceuticals (AGIO) Faces Downgrade Amid Sickle Cell Drug Data - GuruFocus
Agios Pharma stock rating downgraded by RBC Capital after mixed trial data - Investing.com
Why Shares in Agios Pharmaceuticals Got Crushed Today - The Motley Fool
RBC downgrades Agios to Sector Perform after mitapivat ‘falls short’ - TipRanks
Agios Pharmaceuticals (AGIO) Faces Uncertainty After Trial Resul - GuruFocus
Crude Oil Falls Over 2%; Lowe's Shares Gain After Q3 Results - Benzinga
Agios Pharmaceuticals (AGIO) Sees Sharp Decline in Stock Price - GuruFocus
Agios shares fall on mixed sickle cell results for blood disease drug - BioPharma Dive
Why Is Agios Pharmaceuticals Stock Sinking Today? - Benzinga
1.38%
1.42%
자본화:
|
볼륨(24시간):